摘要:
The invention relates to compounds of structural formula (Ia): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, X4, X6, X10, R1, Y, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
摘要:
Compounds of formula II are described, wherein D, n, R a , R b , and R c are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
摘要:
Provided is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A is C 6-10 arylene, etc.; R 1a , R 1b and R 1c each independently is a hydrogen atom, a halogen atom, a C 1-4 alkyl group, a C 1-4 alkoxy group, etc.; R 2 is an optionally substituted C 6-10 aryl group, an optionally substituted 5- to 12-membered monocyclic or polycyclic heteroaryl group, an optionally substituted C 7-16 aralkyl group, etc.; m is 0, etc.; n is an integer of 0 to 2.)
摘要翻译:提供由式(1)表示的化合物或其药理学上可接受的盐。 (式中,A为C 6-10亚芳基等; R 1a,R 1b和R 1c各自独立地为氢原子,卤原子,C 1-4烷基,C 1-4烷氧基 R 2为任选取代的C 6-10芳基,任选取代的5至12元单环或多环杂芳基,任选取代的C 7-16芳烷基等; m为0等 。; n为0〜2的整数。)
摘要:
Provided in certain embodiments are new methods for forming azido modified nucleic acid conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling nucleic acids with an azide group.
摘要:
The present invention provides a compound of formula I';
or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , B 1 , X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要:
Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is -CONH-, etc.; R 1 is a substitutable aminosulfonyl group, etc.; R 2 is a hydrogen atom, etc.; R 3 is a hydrogen atom, etc.; R 4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C 1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R 5a , R 5b and R 5c are each independently hydrogen atoms, etc.; R 6 is a halogen atom, a cyano group, etc.; R 7 and R 8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.)
摘要:
Disclosed are new substituted oxazole and thiazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof.